Optimus Pharma launches COVID-19 drug Molnupiravir, know price and other details

New Delhi: Optimus Pharma launched Molnupiravir, an anti-COVID tablet, for restricted use in emergency situations, in Hyderabad on Thursday, December 30, 2021. Molnupiravir is an antiviral that inhibits the replication of corona by viral mutagenesis. Tablets are authorized for anyone who is 18 years of age or older. Once a person is tested positive for COVID-19, he/she will have to take two 800 mg tablets for 5 days to complete the treatment. It is worth noting that the cost of each anti-covid pill of Molnupiravir is Rs 63. Earlier, expanding India’s basket of COVID-19 vaccines, the country’s drug regulator, the Drugs Controller General of India (DCGI), gave the much-awaited anti-Covid pill Molnupiravir for restricted use in emergency situations. Meanwhile, the company said in a press release that it has successfully completed Phase III clinical trials on 1,218 subjects at 29 geographic study sites across India. (covid-19 medicine)

also read: Batting coach gives tips to Kohli, should stop playing cover drives to prevent getting out

Capable of reducing viral load in 5 days

We aim to capture the maximum demographic diversity in our trial to obtain data across different geographies of the country and have conclusive evidence that molnupiravir is capable of causing viral load reduction within 5 days of the treatment period, said Optimus Chairman and Managing Director Pharma, D Srinivas Reddy said. Optimus Pharma has revealed highly promising results of the drug in its ability to reduce viral load and lead to significant symptomatic improvement in patient health. Meanwhile, Sun Pharma earlier in the day said its subsidiary has received emergency use authorization from the Drug Controller General of India (DCGI) to manufacture and market the generic version of Molnupiravir, an antiviral drug from MSD and Ridgeback under the brand name Moloxvir. (EUA) has been received. in India.

13 companies to treat adult patients with COVID-19 ( covid-19 medicine )

Health Minister Mandaviya said the antiviral drug will now be manufactured by 13 companies in the country for restricted use in emergency situations to treat adult patients of COVID-19 who are at high risk of developing the disease. The UK MHRA on 4 December approved mollupirvir under special circumstances for the treatment of mild to moderate coronavirus disease in adults with a positive corona diagnostic test and who have at least one risk factor for the development of severe disease, the statement said. Is. The US FDA on 23 December granted positive results of a direct SARS-CoV-2 viral trial to the EUA for mollupiravir for the treatment of mild to moderate coronavirus disease in adults, and who are at high risk for progression. For severe COVID-19, including hospitalization or death, and for whom FDA-authorized alternative COVID-19 treatment options are not accessible or medically appropriate. (covid-19 medicine)

People News Chronicle

People News Chronicle author account is for interns, who are just new to our news agency. They are taught basics of wordpress and publishing through this account.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button